Major lifetime events and clinical features in 202 children having Duchenne muscular dystrophy
WANG Yayu1,2 WU Shiwen1,2
1.Clinical College of General Hospital of Armed Police Force, Anhui Medical University, Beijing 100039, China; 2. Department of Neurology, General Hospital of Chinese People’s Armed Police Force, Beijing 100039, China
Abstract：Objective To analyze the major lifetime events and clinical features in children suffering from Duchenne muscular dystrophy (DMD). Methods Two hundred and two DMD patients were diagnosed. Data of the patients were collected and the natural history of DMD analyzed, including motor, cognitive, heart and respiratory functions.Results Mean age of the patients independent ambulation was (17.50±4.84) years and the onset age was about (3.32±1.87) years. The main reasons for visiting doctors were walking slowly and frequent falls. About 45.1% of patients began their first walking after 18 months old. About 94.5% of patients had gastrocnemius muscle pseudohypertrophy, and 72.2% of patients aged from 5 to 7 years old were Gower’s sign positive. Exon deletion was the most frequent genetic mutation in these patients. 8% of patients demonstrated mental retardation (scores<70). 80 of 136 patients had abnormal electrocardiograms changes, 67 of 142 patients had abnormal electrocardiography changes. The SNIP averaged (60.12±16.96)cm H2O in the patients aged 5.0 to 12.9 years. Conclusions The natural history of DMD children follows the unvarying rule. They usually manifest delay in learning walk, stair climbing problem, and difficulty in walking after one hour. It is very important to understand the pathological change characteristics of cardio-pulmonary function in DMD children and early diagnosis and prevention in retarding the progress of diseases and improing quality of life of DMD children.
王亚玉,吴士文. Duchenne 型假肥大肌营养不良症患儿主要生活事件及其临床特点分析[J]. 武警医学, 2016, 27(2): 129-132.
WANG Yayu WU Shiwen. Major lifetime events and clinical features in 202 children having Duchenne muscular dystrophy. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(2): 129-132.
Bushby K, Finkel R, Birnkrant D J, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management[J]. Lancet Neurol, 2010, 9(1):77-93.
[2]
Bushby K M, Hill A, Steele J G.Failure of early diagnosis in symptomatic Duchenne muscular dystrophy[J]. Lancet, 1999, 353(9152):557-558.
WHO Multicentre Growth Reference Study Group.WHO Motor Development Study: windows of achievement for six gross motor development milestones[J]. Acta Paediatr Suppl, 2006, 450:86-95.
Bresolin N, Castelli E, Comi G P, et al. Cognitive impairment in Duchenne muscular dystrophy[J]. Neuromuscl Disord, 1994, 4(4):359-369.
[8]
Nardes F, Araújo A P, Ribeiro M G.Mental retardation in Duchenne muscular dystrophy[J]. J Pediatr (Rio J), 2012, 88(1):6-16.
[9]
Giglio V, Pasceri V, Messano L, et al. Ultrasound tissue characterization detects preclinical myocardial structural changes in children affected by Duchenne muscular dystrophy [J]. J Am Coll Cardiol, 2003, 42(2):309-316.
[10]
Nigro G, Comi L I, Politano L, et al. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy [J]. Int J Cardiol, 1990, 26(3):271-277.
[11]
Klitzner T S, Beckman R H, Galioto F M, et al. Cardiovascular health supervision for individuals affected by Duehenne or Becker muscular dystrophy[J]. Pediatrics, 2005, 116(6):1569-1573.
[12]
Ishikawa Y, Miura T, Ishikawa Y, et al. Duchenne muscular dystrophy: survival by cardiorespiratory interventions [J]. Neuromuscul Disord, 2011, 21:47-51.
2016, Vol. 27 
